Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group.
Pierre Alain RebouxHenri AzaisCharles Henry CanovaSofiane BendifallahLobna OuldamerEmilie RaimondDelphine HudryCharles CoutantOlivier GraesslinCyril TouboulPierre CollinetAlexandre BricouCyrille HuchonEmile DaraïMarcos BallesterJean LévêqueVincent LavoueMartin KoskasCatherine UzanGeoffroy CanlorbePublished in: Journal of gynecologic oncology (2019)
VB is an efficient adjuvant treatment for patients with HIR EC. VB is not associated with an improvement of RFS or OS in IR EC patient.